Last update : 07/21/2015 | Version : 2 | ID : 60149
General | |
Identification | |
Detailed name | Genomics of Resistance/Susceptibility to HIV-1 Infection |
Sign or acronym | GRIV |
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | Accord CNIL : 10/04/1995 |
General Aspects | |
Medical area |
Biology Infectious diseases |
Health determinants |
Genetic |
Keywords | CD4 + lymphocyte count, non-progressors, viral load, clinical events, rapid release, documented seroconversion, Health episodes, seropositivity, follow-up |
Scientific investigator(s) (Contact) | |
Name of the director | Zagury |
Surname | Jean-Francois |
Address | 75003 PARIS |
zagury@cnam.fr | |
Unit | CHAIRE DE BIOINFORMATIQUE CNAMLaboratoire de physiologie cellulaire |
Organization | CNAM |
Collaborations | |
Participation in projects, networks and consortia |
Yes |
Funding | |
Funding status |
Public |
Details | SIDACTION, ANRS, Ministère de l'Education, de la Recherche et de la Technologie |
Governance of the database | |
Sponsor(s) or organisation(s) responsible | CHAIRE DE BIOINFORMATIQUE CNAM |
Organisation status |
Public |
Additional contact | |
Main features | |
Type of database | |
Type of database |
Study databases |
Study databases (details) |
Cohort study |
Database recruitment is carried out by an intermediary |
A selection of health institutions and services |
Database recruitment is carried out as part of an interventional study |
No |
Additional information regarding sample selection. | Retrospective |
Database objective | |
Main objective | General objective: to determine genetic polymorphisms (variations) which promote/suppress infection and/or progression to AIDS. Secondary objective: to understand the molecular mechanisms of the pathogenesis of HIV-1 infection and the rational development of new treatment or diagnostic strategies resulting from this. |
Inclusion criteria | Non-progressors: untreated individuals that have been seropositive for over 8 years with no clinical signs and with CD4 + lymphocytes above 500/mm3 Rapid progressors: subjects with CD4 + lymphocytes that dropped below 300/mm3 within 3 years after seroconversion |
Population type | |
Age |
Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) |
Population covered |
Sick population |
Gender |
Male Woman |
Geography area |
National |
Detail of the geography area | Multicentric cohort throughout France |
Data collection | |
Dates | |
Date of first collection (YYYY or MM/YYYY) | 09/1995 |
Size of the database | |
Size of the database (number of individuals) |
< 500 individuals |
Details of the number of individuals | 400 |
Data | |
Database activity |
Data collection completed |
Type of data collected |
Clinical data Declarative data Biological data |
Clinical data (detail) |
Direct physical measures Medical registration |
Declarative data (detail) |
Face to face interview |
Biological data (detail) | Type of samples taken: 4 tubes of blood |
Presence of a biobank |
Yes |
Contents of biobank |
Serum DNA |
Details of biobank content | Serum bank, DNA bank |
Health parameters studied |
Health event/morbidity Health event/mortality |
Procedures | |
Data collection method | Interview: from a paper questionnaire (manual input) with double data entry Clinical Examinations: handwritten with double data entry Biological analysis: handwritten with double data entry |
Participant monitoring |
Yes |
Details on monitoring of participants | Indefinite duration |
Links to administrative sources |
No |
Promotion and access | |
Promotion | |
Link to the document | http://tinyurl.com/HAL-GRIV |
Description | List of publications in HAL |
Link to the document | http://www.ncbi.nlm.nih.gov/pubmed/?term=GRIV+AND+Zagury[Author] |
Description | List of publications in Pubmed |
Access | |
Terms of data access (charter for data provision, format of data, availability delay) | Data may be used by academic teams Access permitted for collaboration with other teams working in the same field of AIDS genomics. To be decided if data may be used by industrial teams. |
Access to aggregated data |
Access on specific project only |
Access to individual data |
Access on specific project only |
Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05